ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ZYBT vs OSTX // GROSS PROFIT MARGIN

Zhengye Biotechnology Holding Limited (Class A) (NASDAQ) VS. OS Therapies Incorporated (NYSE) • 15-METRIC TALLY: ZYBT 5 — OSTX 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZYBT VS. OSTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ZYBT OSTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE 20.50% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -22.30% -35.00% +12.70 ZYBT /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield 2.61% -21.07% +23.68 ZYBT /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -34.80% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 1.90 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 1/9 +3.00 ZYBT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 43.1 33.8 +9.26 ZYBT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $67.8M $67.6M $185.2K ZYBT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ZYBT REV OSTX REV ZYBT GROSS % OSTX GROSS % ZYBT FCF OSTX FCF
FY 2025 $16.6M $0 20.5% — $1.8M -$14.2M
FY 2024 $25.5M $0 49.0% — $3.8M -$7.3M
FY 2023 — $0 — — — -$3.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZYBT // BETA —
OSTX // BETA —